Almost 50% protective efficacy.Biota and investors have caught...

Almost 50% protective efficacy.

Biota and investors have caught the "glass is half empty" syndrome.

Antivirals are already stated as too expensive to use as prophylaxis by the general population in normal seasons, so the potential for this use is small and only likely during pandemics - if I was at risk, I'd happily take if there was a quoted almost 50% protective efficacy. For certain members of the population that might be a target, I believe 50% versus 70% is a justified improvement.

Market has caned 10% on this news - completely uneducated - this news has nothing to do with standard use of LANI, which is 100% of how it is to be used under upcoming US Phase III trials and current Japan approvals.

I doubt whether LANI as a prophylaxis was valued in at more than 2% of the price.